You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors

Article Text

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors

https://doi.org/10.1136/jitc-2023-SITC2023.0278

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.